Christopher Nutting, MD, PhD, of the Royal Marsden Hospital and Institute of Cancer Research, discusses phase III results from the first study to demonstrate the functional benefit of swallow-sparing intensity-modulated radiotherapy in oro- and hypopharyngeal cancers (Abstract 6508).
Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses early results on a cereblon E3 ligase modulator agent combined with dexamethasone in patients with relapsed...
Merry-Jennifer Markham, MD, ASCO’s Cancer Communications Chair, gives her views on key papers presented at th...
Michael S. Hofman, MBBS, of the Peter MacCallum Cancer Centre, discusses phase II results from the ANZUP 1603 trial, which showed that in men with docetaxel-treated metastati...
Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses phase III results of the HERO study, which showed relugolix achieved castration as early as day 4 and w...
Rachel E. Sanborn, MD, of the Providence Cancer Institute, discusses three key abstracts on EGFR-mutated non–small cell lung cancer: a final overall survival analysi...
